PCRX Stock Analysis: Buy, Sell, or Hold?
PCRX - Pacira BioSciences, Inc. Common Stock
$25.39
0.36 (1.44%)
▲
5d:
+4.19%
30d:
+14.11%
90d:
+11.41%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 04, 2026
30d
Get Alerted When PCRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PCRX shows positive signals but monitor for confirmation. Market pricing in 1.5% growth. Moderate conviction.
💡 BUY OPPORTUNITY: PCRX shows positive signals but monitor for confirmation. Market pricing in 1.5% growth. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$46.88
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$29.11
12.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PCRX is currently trading at $25.39, which is considered extended relative to its 30-day fair value range of $22.55 to $24.51. The stock's valuation (Forward PE: 7.0) is in line with its historical norms (6.6). At these levels, the market is pricing in 1.5% annual earnings growth.
Technical Outlook: Technically, PCRX is in a uptrend. Immediate support is located at $22.00, while resistance sits at $26.21.
Market Sentiment: PCRX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $29.67 (+16.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PCRX is in a uptrend. Immediate support is located at $22.00, while resistance sits at $26.21.
Market Sentiment: PCRX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $29.67 (+16.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$22.55 -
$24.51
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
62.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($29.67)
- BULLISH: Expecting earnings turnaround to 1.5% growth with 5.0% revenue growth
Trading Range Analysis
30-Day Trading Range
$22.55 -
$24.51
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$22.00
Resistance Level
$26.21
Current Trend
Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.96
Wall Street Target
$29.67
(+16.8%)
Revenue Growth (YoY)
5.0%
Earnings Growth (YoY)
-30.0%
Profit Margin
0.7%
Valuation Premium vs History
+1.5% premium
PE vs Historical
7.0 vs 6.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.5%
(market-implied from PE analysis)
1-Year Target
$25.77
(+2%)
2-Year Target
$26.16
(+3%)
3-Year Target
$26.55
(+5%)
3-Yr Target (if PE normalizes)
(PE: 7→7)
PE COMPRESSION
$25.18
(-1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 26.8%)
$161.94
(+538%)
Base:
(SPY PE: 7.0, Growth: 26.8%)
$51.75
(+104%)
Bear:
(PE: 5.9, Growth: 26.8%)
$43.99
(+73%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (9x PE), but valuation improves significantly next year (7x PE) as earnings recover.
Forward PE: 8.67 | Forward EPS (Implied): $2.93
Bull Case
$30.66
(+21%)
Analyst growth 15.0%, PE expands to 9.1
Base Case
$25.39
(0%)
Market implied 0.0%, PE stable at 8.7
Bear Case
$19.42
(-24%)
Severe decline -15.0%, PE contracts to 7.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 04, 2026 5:50 PM ET
Data refreshes hourly during market hours. Next update: 6:50 PM
Data refreshes hourly during market hours. Next update: 6:50 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PCRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Shawn Cross
SELL
12941 shares
2026-04-23
Shawn Cross
SELL
1500 shares
2026-04-22
Shawn Cross
SELL
2845 shares
2026-04-21
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 62 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 63 BUY |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 61 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 54 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 60 HOLD |
